Sponsored Article
By Elric Langton | 18th January 2022
OptiBiotix Health plc (AIM: OPTI), a wholly-owned subsidiary, ProBiotix Health Ltd, has published a third human volunteer study on its cholesterol-reducing probiotic, Lactobacillus Plantarum ECGC13110402, branded as LP-LDL, which is significant in several ways and may alert Big pharma to LP-LDL.